Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Assets (2022 - 2026)

Compass Therapeutics' Assets history spans 5 years, with the latest figure at $205.2 million for Q1 2026.

  • On a quarterly basis, Assets rose 56.08% to $205.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $205.2 million, a 56.08% increase, with the full-year FY2025 number at $219.6 million, up 56.4% from a year prior.
  • Assets hit $205.2 million in Q1 2026 for Compass Therapeutics, down from $219.6 million in the prior quarter.
  • Over the last five years, Assets for CMPX hit a ceiling of $231.3 million in Q3 2025 and a floor of $116.7 million in Q2 2025.
  • Historically, Assets has averaged $171.7 million across 5 years, with a median of $165.6 million in 2023.
  • The widest YoY moves for Assets: up 56.4% in 2025, down 25.01% in 2025.
  • Tracing CMPX's Assets over 5 years: stood at $199.6 million in 2022, then decreased by 21.42% to $156.9 million in 2023, then dropped by 10.5% to $140.4 million in 2024, then skyrocketed by 56.4% to $219.6 million in 2025, then decreased by 6.57% to $205.2 million in 2026.
  • Business Quant data shows Assets for CMPX at $205.2 million in Q1 2026, $219.6 million in Q4 2025, and $231.3 million in Q3 2025.